Loading...
Market
Tagrisso's market share in EGFR-mutated lung cancer treatments by end of 2024
5
Resolution / Starting Odds
Less than 20% • 33%
20% to 40% • 33%
Greater than 40% • 34%
Market research reports, AstraZeneca financial reports
Story
AstraZeneca's Tagrisso Shows 84% Reduction in Disease Progression in Trials
Jun 2, 2024, 01:30 PM
Tagrisso, one of AstraZeneca's drugs, greatly slowed cancer progression for patients with stage 3 lung cancer, particularly those with a specific genetic mutation, achieving a major PFS benefit (HR=0.16). The drug reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer compared to a placebo in the LAURA Phase III trial, with a median progression-free survival of several years. These results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%